Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

2
results for

"Sung Hoon Choi"

Article category

Keywords

Publication year

"Sung Hoon Choi"

Original Articles

Liver Transplantation

Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma
Incheon Kang, Jae Geun Lee, Sung Hoon Choi, Hyun Jeong Kim, Dai Hoon Han, Gi Hong Choi, Myoung Soo Kim, Jin Sub Choi, Soon Il Kim, Dong Jin Joo
Clin Mol Hepatol 2021;27(4):589-602.
Published online July 23, 2021
DOI: https://doi.org/10.3350/cmh.2021.0038
Background/Aims
This study aimed to investigate whether everolimus (EVR) affects long-term survival after liver transplantation (LT) in patients with hepatocellular carcinoma (HCC).
Methods
The data from 303 consecutive patients with HCC who had undergone LT from January 2012 to July 2018 were retrospectively reviewed. The patients were divided into two groups: 1) patients treated with EVR in combination with calcineurin inhibitors (CNIs) (EVR group; n=114) and 2) patients treated with CNI-based therapy without EVR (non-EVR group; n=189). Time to recurrence (TTR) and overall survival (OS) after propensity score (PS) matching were compared between the groups, and prognostic factors for TTR and OS were evaluated.
Results
The EVR group exhibited more aggressive tumor biology than the non-EVR group, such as a higher number of tumors (P=0.003), a higher prevalence of microscopic vascular invasion (P=0.017) and exceeding Milan criteria (P=0.029). Compared with the PS-matched non-EVR group, the PS-matched EVR group had significantly better TTR (P<0.001) and OS (P<0.001). In multivariable analysis, EVR was identified as an independent prognostic factor for TTR (hazard ratio [HR], 0.248; P=0.001) and OS (HR, 0.145; P<0.001).
Conclusions
Combined with CNIs, EVR has the potential to prolong long-term survival in patients undergoing LT for HCC. These findings warrant further investigation in a well-designed prospective study.

Citations

Citations to this article as recorded by  Crossref logo
  • Everolimus Personalized Therapy: Second Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
    Satohiro Masuda, Florian Lemaitre, Markus J. Barten, Stein Bergan, Maria Shipkova, Teun van Gelder, Sander Vinks, Eberhard Wieland, Kirsten Bornemann-Kolatzki, Mercè Brunet, Brenda de Winter, Maja-Theresa Dieterlen, Laure Elens, Taihei Ito, Kamisha Johnso
    Therapeutic Drug Monitoring.2025; 47(1): 4.     CrossRef
  • Genetic alterations are related to clinicopathological features and risk of recurrence/metastasis of hepatocellular carcinoma
    Lili Meng, Zhenjian Jiang, Guangyue Shen, Shulan Lin, Feng Gao, Xinxin Guo, Bin Lv, Shuying Hu, Zheng Ni, Shanghua Chen, Yuan Ji
    European Journal of Cancer Prevention.2025; 34(5): 456.     CrossRef
  • Association between everolimus combination therapy and cancer risk after liver transplantation: A nationwide population-based quasi-cohort study
    Suk-Chan Jang, Gi-Ae Kim, Young-Suk Lim, Hye-Lin Kim, Eui-Kyung Lee
    American Journal of Transplantation.2025; 25(6): 1285.     CrossRef
  • Adjuvant chemotherapy improves post-transplant outcome in patients with hepatocellular carcinoma
    Heng-Kai Zhu, Hai-Bo Mou, Zhuo-Yi Wang, Wu Zhang, Dan Zhu, Si-Yi Zhong, Shu-Sen Zheng, Li Zhuang
    Hepatobiliary & Pancreatic Diseases International.2025; 24(5): 491.     CrossRef
  • Optimizing patient selection and immunosuppression in improving long-term survival after living donor liver transplantation for hepatocellular carcinoma
    JaRyung Han, Young Seok Han
    Annals of Liver Transplantation.2025; 5(1): 1.     CrossRef
  • Cellular Cancer Immunotherapy in the Liver Transplant Population for HCC: An Attractive Therapeutic Option for the Next Decade
    Dongdong Yu, Shuchan Li, Hao Chen, Lidong Wang
    Clinical Transplantation.2025;[Epub]     CrossRef
  • Toward optimized immunosuppression balance in liver transplantation: Clinical insights from lower tacrolimus exposure
    Sung-Min Kim
    Annals of Liver Transplantation.2025; 5(2): 65.     CrossRef
  • High Number of Plasma Exchanges Increases the Risk of Bacterial Infection in ABO-incompatible Living Donor Liver Transplantation
    Mun Chae Choi, Eun-Ki Min, Seung Hyuk Yim, Deok-Gie Kim, Jae Geun Lee, Dong Jin Joo, Myoung Soo Kim
    Transplantation.2024; 108(8): 1760.     CrossRef
  • Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantation
    Dong-Sik Kim, Young-In Yoon, Beom Kyung Kim, Ashok Choudhury, Anand Kulkarni, Jun Yong Park, Jongman Kim, Dong Hyun Sinn, Dong Jin Joo, YoungRok Choi, Jeong-Hoon Lee, Ho Joong Choi, Ki Tae Yoon, Sun Young Yim, Cheon-Soo Park, Deok-Gie Kim, Hae Won Lee, Wo
    Hepatology International.2024; 18(2): 299.     CrossRef
  • Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation
    Paolo De Simone, Arianna Precisi, Quirino Lai, Juri Ducci, Daniela Campani, Piero Marchetti, Stefano Gitto
    Cancers.2024; 16(7): 1243.     CrossRef
  • Liver Transplantation for Hepatocarcinoma: Results over Two Decades of a Transplantation Programme and Analysis of Factors Associated with Recurrence
    María Martínez Burgos, Rocío González Grande, Susana López Ortega, Inmaculada Santaella Leiva, Jesús de la Cruz Lombardo, Julio Santoyo Santoyo, Miguel Jiménez Pérez
    Biomedicines.2024; 12(6): 1302.     CrossRef
  • Hepatocellular carcinoma recurrence after liver transplantation: risk factors, targeted surveillance and management options
    Filippo Pelizzaro, Alberto Ferrarese, Martina Gambato, Alberto Zanetto, Francesco Paolo Russo, Giacomo Germani, Marco Senzolo, Mario Domenico Rizzato, Caterina Soldà, Alessandro Vitale, Enrico Gringeri, Umberto Cillo, Patrizia Burra
    Hepatoma Research.2024;[Epub]     CrossRef
  • Sirolimus improves the prognosis of liver recipients with hepatocellular carcinoma: A single-center experience
    Peng Liu, Xin Wang, Huan Liu, Shu-Xian Wang, Qing-Guo Xu, Lin Wang, Xiao Xu, Jin-Zhen Cai
    Hepatobiliary & Pancreatic Diseases International.2023; 22(1): 34.     CrossRef
  • Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management
    Sara Battistella, Francesca D’Arcangelo, Marco Grasso, Alberto Zanetto, Martina Gambato, Giacomo Germani, Marco Senzolo, Francesco Paolo Russo, Patrizia Burra
    Clinical and Molecular Hepatology.2023; 29(Suppl): S286.     CrossRef
  • 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

    Journal of Liver Cancer.2023; 23(1): 1.     CrossRef
  • Immunosuppressive Medication Adherence in Patients With Hepatocellular Cancer Who Have Undergo Liver Transplantation: A Case Control Study
    Sami Akbulut, Murat Tamer, Serdar Saritas, Ozlem Unal, Musap Akyuz, Selver Unsal, Zeynep Kucukakcali, Ertugrul Karabulut, Sertac Usta, Sezai Yilmaz
    Transplantation Proceedings.2023; 55(5): 1231.     CrossRef
  • Risk factors for late-onset Pneumocystis jirovecii pneumonia in liver transplant recipients
    Eun-Ki Min, Juhan Lee, Su Jin Jeong, Deok-Gie Kim, Seung Hyuk Yim, Mun Chae Choi, Dong Jin Joo, Myoung Soo Kim, Jae Geun Lee
    International Journal of Infectious Diseases.2023; 131: 166.     CrossRef
  • Metronomic capecitabine with rapamycin exerts an immunosuppressive effect by inducing ferroptosis of CD4+ T cells after liver transplantation in rat
    Hao Wang, Ruining Yang, Zhenglu Wang, Lei Cao, Dejun Kong, Qian Sun, Sei Yoshida, Jiashu Ren, Tao Chen, Jinliang Duan, Jianing Lu, Zhongyang Shen, Hong Zheng
    International Immunopharmacology.2023; 124: 110810.     CrossRef
  • Association between the early high level of serum tacrolimus and recurrence of hepatocellular carcinoma in ABO-incompatible liver transplantation
    Ji Won Han, Jong Young Choi, Eun Sun Jung, Ji Hoon Kim, Hee Sun Cho, Jae-Sung Yoo, Pil Soo Sung, Jeong Won Jang, Seung Kew Yoon, Ho Joong Choi, Young Kyoung You
    World Journal of Gastrointestinal Surgery.2023; 15(12): 2727.     CrossRef
  • Safety of Tacrolimus Monotherapy within 12 Months after Liver Transplantation in the Era of Reduced Tacrolimus and Mycophenolate Mofetil: National Registry Study
    Deok Gie Kim, Sung Hwa Kim, Shin Hwang, Suk Kyun Hong, Je Ho Ryu, Bong-Wan Kim, Young Kyoung You, Donglak Choi, Dong-Sik Kim, Yang Won Nah, Jai Young Cho, Tae-Seok Kim, Geun Hong, Dong Jin Joo, Myoung Soo Kim, Jong Man Kim, Jae Geun Lee
    Journal of Clinical Medicine.2022; 11(10): 2806.     CrossRef
  • 2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

    Korean Journal of Radiology.2022; 23(12): 1126.     CrossRef
  • 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

    Clinical and Molecular Hepatology.2022; 28(4): 583.     CrossRef
  • Clinical association between tacrolimus intra-patient variability and liver transplantation outcomes in patients with and without hepatocellular carcinoma
    Hyun Jeong Kim, Juhan Lee, Jae Geun Lee, Dong Jin Joo, Myoung Soo Kim
    Scientific Reports.2022;[Epub]     CrossRef
  • The first successful report of liver transplantation from category III donation after circulatory death in South Korea: a case report
    Incheon Kang, Jae-myeong Lee, Jae Geun Lee
    Korean Journal of Transplantation.2022; 36(4): 294.     CrossRef
  • Can hepatocellular carcinoma recurrence be prevented after liver transplantation?
    Jong Man Kim
    Clinical and Molecular Hepatology.2021; 27(4): 562.     CrossRef
  • Human Cytomegalovirus Is Associated with Lower HCC Recurrence in Liver Transplant Patients
    Po-Jung Hsu, Hao-Chien Hung, Jin-Chiao Lee, Yu-Chao Wang, Chih-Hsien Cheng, Tsung-Han Wu, Ting-Jung Wu, Hong-Shiue Chou, Kun-Ming Chan, Wei-Chen Lee, Chen-Fang Lee
    Current Oncology.2021; 28(6): 4281.     CrossRef
  • Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma
    Soon Kyu Lee, Sung Won Lee, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon
    International Journal of Molecular Sciences.2021; 22(19): 10271.     CrossRef
  • Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation
    Filippo Pelizzaro, Martina Gambato, Enrico Gringeri, Alessandro Vitale, Umberto Cillo, Fabio Farinati, Patrizia Burra, Francesco Paolo Russo
    Cancers.2021; 13(19): 4882.     CrossRef
  • 11,677 View
  • 265 Download
  • 27 Web of Science
  • Crossref
Effects of the knockdown of hypoxia inducible factor-1α expression by adenovirus-mediated shRNA on angiogenesis and tumor growth in hepatocellular carcinoma cell lines
Sung Hoon Choi, Hye Won Shin, Jun Yong Park, Ji Young Yoo, Do Young Kim, Weon Sang Ro, Chae-Ok Yun, Kwang-Hyub Han
Korean J Hepatol 2010;16(3):280-287.
Published online September 30, 2010
DOI: https://doi.org/10.3350/kjhep.2010.16.3.280
Background/Aims

Hypoxia-inducible factor-1α (HIF-1α) is a central transcriptional factor involved in the cellular responses related to various aspects of cancer biology, including proliferation, survival, and angiogenesis, and the metabolism of the extracellular matrix in hypoxia. This study evaluated whether adenovirus-mediated small hairpin RNA (shRNA) against HIF-1α (shHIF-1α) inhibits cell proliferation and angiogenesis in hepatocellular carcinoma (HCC) cell lines.

Methods

Knockdown of HIF-1α expression was constructed by adenovirus-mediated RNA interference tools, and HCC cell lines infected with shHIF-1α coding virus were cultured under a hypoxia condition (1% O2) for 24 hours. Following infection, the expression levels of HIF-1α, angiogenesis factors, and matrix metalloproteinase (MMP) were examined using Western blotting. Cell proliferation and angiogenesis were measured by a cell proliferation assay (MTT assay) and an angiogenesis-related assay (invasion and tube-formation assay), respectively.

Results

Adenovirus mediated inhibition of HIF-1α induced suppression of tumor growth in HCC cell lines. It also down-regulated the expression of angiogenesis factor and MMP proteins. Angiogenesis as well as mobility of vascular cells to tumor was suppressed by adenovirus-mediated shHIF-1α-infected groups in human umbilical vein endothelial cells (HUVECs).

Conclusions

These data suggest that adenovirus-mediated inhibition of HIF-1α inhibits the invasion, tube formation, and cell growth in HUVECs and HCC cells.

Citations

Citations to this article as recorded by  Crossref logo
  • Therapeutic Synergy of Silibinin‐Loaded Nanogel and Low‐Dose Gamma Radiation in Hepatocellular Carcinoma: Emphasis on EMT, Angiogenesis, and Immune Response
    Zakaria Mohamed Alghzzawy, Mohammed Hussein Awwad, Tarek Khaled Elmaghraby, Sanaa Abd El‐Hamid Hagag, Azza Elsayed Kayed, Doaa Sabry Ibrahim
    Advanced Therapeutics.2025;[Epub]     CrossRef
  • RSK2-Mediated ELK3 Activation Enhances Cell Transformation and Breast Cancer Cell Growth by Regulation of c-fos Promoter Activity
    Sun-Mi Yoo, Cheol-Jung Lee, Hyun-Jung An, Joo Young Lee, Hye Suk Lee, Han Chang Kang, Sung-Jun Cho, Seung-Min Kim, Juhee Park, Dae Joon Kim, Yong-Yeon Cho
    International Journal of Molecular Sciences.2019; 20(8): 1994.     CrossRef
  • Stable knockdown of CREB, HIF-1 and HIF-2 by replication-competent retroviruses abrogates the responses to hypoxia in hepatocellular carcinoma
    D Shneor, R Folberg, J Pe'er, A Honigman, S Frenkel
    Cancer Gene Therapy.2017; 24(2): 64.     CrossRef
  • Tumor angiogenesis and vascular normalization: alternative therapeutic targets
    Claire Viallard, Bruno Larrivée
    Angiogenesis.2017; 20(4): 409.     CrossRef
  • ELK3 promotes the migration and invasion of liver cancer stem cells by targeting HIF-1α
    Joon Ho Lee, Wonhee Hur, Sung Woo Hong, Jung-Hee Kim, Sung Min Kim, Eun Byul Lee, Seung Kew Yoon
    Oncology Reports.2017; 37(2): 813.     CrossRef
  • RNAi Knockdown of Hypoxia-Inducible Factor-1α Decreased the Proliferation, Migration, and Invasion of Hypoxic Hepatocellular Carcinoma Cells
    ChengShi Chen, Rong Liu, JianHua Wang, ZhiPing Yan, Sheng Qian, Wei Zhang
    Cell Biochemistry and Biophysics.2015; 71(3): 1677.     CrossRef
  • Inhibition of tumour angiogenesis and growth by small hairpin HIF‐1α and IL‐8 in hepatocellular carcinoma
    Sung Hoon Choi, Oh‐Joon Kwon, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim, Simon Weonsang Ro, Kyung Sik Kim, Jeon Han Park, Seungtaek Kim, Chae‐Ok Yun, Kwang‐Hyub Han
    Liver International.2014; 34(4): 632.     CrossRef
  • The Role of Hypoxia Inducible Factor-1 in Hepatocellular Carcinoma
    Dongjun Luo, Zhongxia Wang, Junyi Wu, Chunping Jiang, Junhua Wu
    BioMed Research International.2014; 2014: 1.     CrossRef
  • Expression and significance of MMP2 and HIF-1α in hepatocellular carcinoma
    BIN WANG, YOU-MING DING, PING FAN, BING WANG, JUN-HUI XU, WEI-XING WANG
    Oncology Letters.2014; 8(2): 539.     CrossRef
  • Signaling pathways bridging microbial-triggered inflammation and cancer
    Maulilio John Kipanyula, Paul Faustin Seke Etet, Lorella Vecchio, Mohammed Farahna, Elias Nchiwan Nukenine, Armel Hervé Nwabo Kamdje
    Cellular Signalling.2013; 25(2): 403.     CrossRef
  • The role of Aurora A in hypoxia-inducible factor 1α-promoting malignant phenotypes of hepatocelluar carcinoma
    Shi-Yun Cui, Jia-Yuan Huang, Yi-Tian Chen, Hai-Zhu Song, Gui-Chun Huang, Wei De, Rui Wang, Long-Bang Chen
    Cell Cycle.2013; 12(17): 2849.     CrossRef
  • Hypoxia-inducible factor 1, hepatocellular carcinoma and angiogenesis
    Jin-Wook Kim
    The Korean Journal of Hepatology.2010; 16(3): 278.     CrossRef
  • 11,305 View
  • 68 Download
  • Crossref